Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Some patients dropped out of the trial early because they had lost so much weight.

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

Dec 11 () - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ​late-stage trial, outperforming its blockbuster drug Zepbound and ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Tan France is using his experience in fashion way beyond styling. Now, the Queer Eye staple is partnering with Lilly, the makers of Zepbound, for the Changing the Thread Collection™, the first ...

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...